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Background: We conducted a systematic review comparing the effectiveness and safety of concomitant use of proton pump inhibitor (PPI) and 
dual antiplatelet therapy (DAPT) among patients with coronary artery disease.
methods: Studies dated January 1995 through August 2012 were screened by independent investigators. Investigators identified 32 studies for 
inclusion, extracted data, assessed applicability and study quality, and graded the strength of evidence. Meta-analysis of direct comparison was 
performed when outcomes and follow-up periods were comparable.
results: Five studies (4 RCT, 1 observational) compared DAPT with and without omeprazole. There was insufficient evidence on the effect of 
omeprazole on composite ischemic events, nonfatal MI, stroke, revascularization, or stent thrombosis. Use of omeprazole reduced rates of upper 
gastrointestinal bleeding. Random-effect meta-analyses of 26 observational studies comparing PPI as a class consistently reported lower events 
rates in patients who were not receiving a PPI medication for the various composite outcomes, all-cause mortality after 1 year, nonfatal MI at 1 year, 
stroke at 1 year, revascularization at 1 year, stent thrombosis at 1 year and rehospitalization at 1 year. The findings were inconsistent (i.e., showing 
no differences between groups or showing increased event rates in the PPI group) the evidence base insufficient for bleeding (minor, major and 
gastrointestinal).
conclusions: Large, well-done observational studies of PPI as a class and RCTs of omeprazole seem to provide conflicting results on the effect 
of different PPI on various cardiovascular outcomes when co-administered with DAPT. Prospective trials directly comparing pharmacokinetics 
parameters and clinical events of different PPIs in patients with coronary artery disease treated with DAPT are warranted.
